Mink Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Mink Therapeutics

18/03/2025 13:32

Mink Therapeutics Inc INKT.OQ reported a quarterly adjusted loss of 62 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of $-1.60.  The mean expectation of three analysts for the quarter was for a loss of 50 cents per share.

Reported revenue was zero​; analysts expected zero.

Mink Therapeutics Inc's reported EPS for the quarter was a loss of 62 cents​.

The company reported a quarterly loss of $2.46 million.

Mink Therapeutics Inc shares had risen by 22.3% this quarter.

FORECAST CHANGES

The mean earnings estimate of analysts was unchanged in the last three months.​

In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The average consensus recommendation for the biotechnology & medical research peer group is  "buy."

Wall Street's median 12-month price target for Mink Therapeutics Inc is $40.00

This summary was machine generated from LSEG data March 18 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Dec. 31 2024
-0.50
-0.62
Missed
Sep. 30 2024
-0.80
-0.50
Beat
Jun. 30 2024
-1.00
-0.70
Beat
Mar. 31 2024
-1.53
-1.10
Beat